1. Home
  2. Studies
  3. Where the German Pharmaceutical Industry Sources its Intermediate Inputs: An International Comparison
Jasmina Kirchhoff IW-Trends No. 1 9. February 2022 Where the German Pharmaceutical Industry Sources its Intermediate Inputs: An International Comparison

The Corona pandemic has led to increasing demands for the reshoring of pharmaceutical production back to Germany. A strategic dependence on non-European active ingredient and drug manufacturers is cited as an argument.

Download PDF
An International Comparison
Jasmina Kirchhoff IW-Trends No. 1 9. February 2022

Where the German Pharmaceutical Industry Sources its Intermediate Inputs: An International Comparison

Download PDF Quote

Copy the information

The link was added to your clipboard!

Share this article:

or copy the following link:

The link was added to your clipboard!

German Economic Institute (IW) German Economic Institute (IW)

The Corona pandemic has led to increasing demands for the reshoring of pharmaceutical production back to Germany. A strategic dependence on non-European active ingredient and drug manufacturers is cited as an argument.

However, the German pharmaceutical industry sources most of its medicinal and chemical inputs either domestically or from other European countries. A similarly regional supply structure is to be found in the pharmaceutical and chemical sectors of those countries which supply the majority of intermediate inputs to Germany’s pharmaceutical industry, with those from China and India playing only a subordinate role. There is thus no evidence that German pharmaceutical production is predominantly dependent on these two Asian nations. However, since intermediate inputs are recorded by value, and prices for generic medicines and their active ingredients are much lower than those for innovative products, it is possible that despite China's small share of intermediate input purchases there may be a dependency in the case of certain individual generics. Nonetheless, a strategic boost to pharmaceutical production in Germany is scarcely to be achieved by expanding generic production. What is needed is rather a well-coordinated package of policy measures designed to encourage locally based firms to maintain and make long-term investments in their domestic production facilities and to promote the development of new innovative production. Such a course also pays off in terms of security of supply, since the patented innovative medicines of today are the generics of tomorrow.

Content element with id 10503
Download PDF
An International Comparison
Jasmina Kirchhoff IW-Trends No. 1 9. February 2022

Where the German Pharmaceutical Industry Sources its Intermediate Inputs: An International Comparison

Download PDF Quote

Copy the information

The link was added to your clipboard!

German Economic Institute (IW) German Economic Institute (IW)

Share this article:

or copy the following link:

The link was added to your clipboard!

More on the topic

Read the article
Proposals for more liquidity in private households and companies
Tobias Hentze / Michael Hüther IW-Policy Paper No. 5 24. September 2022

Effective aid programs in the energy price crisis

The energy price crisis is a huge challenge for economic policy. With the three relief packages, the government has given some important support, but the economic policy lacks a stringent line. All measures should currently have the top priority to secure ...

IW

Read the article
Florian Blank / Johannes Geyer, Peter Haan, Maximilian Schaller / Jochen Pimpertz / Reinhold Thiede / Martin Werding IW-Trends No. 2 6. July 2022

Should the State Pension Scheme Take Different Socio-demographic Backgrounds into Account?

While German law stipulates a standard retirement age for all members of the public pension scheme, empirical studies have shown that life expectancy is unevenly distributed within the population, varying according to income level, professional status, ...

IW

More about this topic

Content element with id 8880 Content element with id 9713